315 results on '"Conconi, Annarita"'
Search Results
2. IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma
3. Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy
4. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
5. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma
6. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
7. Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma
8. Impact of immunochemotherapy with R‐bendamustine or R‐CHOP for treatment naïve advanced‐stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi
9. A MALT lymphoma prognostic index
10. Time to Complete Response within 24 Months As a Good Surrogate Marker of 8 Year-Progression Free Survival in Extranodal Marginal Zone Lymphoma
11. Revised MALT‐IPI: A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma
12. Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma
13. Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL)
14. Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL)
15. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group
16. Prognostic impact of monocyte count at presentation in mantle cell lymphoma – response to George et al
17. Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi
18. Prognostic impact of monocyte count at presentation in mantle cell lymphoma
19. Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice
20. Incidence, risk factors and outcome of histological transformation in follicular lymphoma
21. Primary effusion lymphoma
22. ABCL-135: RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
23. Review for "Immunomodulatory treatment for mucosa‐associated lymphoid tissue lymphoma ( MALT lymphoma)"
24. Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL)
25. Safe and effective use of plerixafor plus G-CSF in dialysis-dependent renal failure
26. Monitoring of cytomegalovirus reactivation during induction and nontransplant consolidation of acute leukemia
27. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome
28. Transient monoclonal expansion of CD8+/CD57+ T-cell large granular lymphocytes after primary cytomegalovirus infection
29. Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance
30. Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals
31. Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkinʼs Lymphoma Resistant to or Not Eligible for Anti–Helicobacter Pylori Therapy
32. Aberrant somatic hypermutation in post-transplant lymphoproliferative disorders
33. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research
34. Frequent aberrant promoter hypermethylation of O6-methylguanine-DNA methyltransferase and death-associated protein kinase genes in immunodeficiency-related lymphomas
35. Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience
36. Prognostic impact of immunoglobulin genes somatic hypermutation and chromosome 11q22-23 deletion in classical mantle cell lymphoma: A study from the Swiss Group for Clinical Cancer Research (SAKK)
37. Molecular histogenesis of posttransplantation lymphoproliferative disorders
38. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type
39. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
40. Non-gastric MALT lymphomas: a survey of 369 European patients - The International Extranodal Lymphoma Study Group (IELSG).
41. Monocytoid lymphomas may arise from different subsets of marginal zone B lymphocytes.
42. Late relapse in patients with diffuse large B‐cell lymphoma: impact of rituximab on their incidence and outcome
43. Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice
44. Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory Waldenström Macroglobulinemia Patients
45. Molecular follow-up in gastric mucosa–associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial
46. Treatment of extranodal lymphomas
47. Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes
48. High‐dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL‐GITMO
49. Novel acquisitions on biology and management of transformed follicular lymphoma
50. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.